Φορτώνει......
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Immunotherapy |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Future Medicine Ltd
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7319491/ https://ncbi.nlm.nih.gov/pubmed/32546029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2020-0136 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|